Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | MLNR | O43193 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915719 | 0.86 | HRH3 (0.52) | HRH3HRH1MLNRCYP2D6ADRA2A | |
| SCHEMBL4923841 | 0.83 | HRH3 (0.46) | HRH3HRH1CNR2 | |
| SCHEMBL14372311 | 0.83 | HRH3 (0.48) | HRH3HRH1MLNRCYP2D6ADRA2A | |
| SCHEMBL14372307 | 0.82 | HRH3 (0.50) | HRH3HRH1ADRA2AADRA2BADRA2C | |
| SCHEMBL4922884 | 0.81 | HRH3 (0.51) | HRH3HRH1CYP2D6 | |
| SCHEMBL4914350 | 0.81 | HRH3 (0.49) | HRH3HRH1CNR2PARP1 | |
| SCHEMBL4923732 | 0.80 | HRH3 (0.71) | HRH3HRH1MLNRCYP2D6HTR6 | |
| SCHEMBL4923707 | 0.78 | NR1H2 (0.46) | HRH3HRH1CNR2 | |
| SCHEMBL11957011 | 0.71 | CYP2D6 (0.47) | HRH3CYP2D6PARP1 | |
| SCHEMBL1171280 | 0.70 | CNR2 (0.39) | HRH3MLNRCYP2D6CNR2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| EP-1735299-A1 | TERTRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097778-A1 | TETRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885MLNR 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.